Erratum: Corrigendum to ‘Synthesis of (2R,8′S,3′E)-δ-tocodienol, a tocoflexol family member designed to have a superior pharmacokinetic profile compared to δ-tocotrienol’ (Tetrahedron (2016) 72(27–28) (4001–4006))

Xingui Liu, Satheesh Gujarathi, Xuan Zhang, Lijian Shao, Marjan Boerma, Cesar M. Compadre, Peter A. Crooks, Martin Hauer-Jensen, Daohong Zhou, Guangrong Zheng

Producción científica: Comment/debaterevisión exhaustiva

Resumen

The authors regret that the following statement was omitted from the Acknowledgements section of the above published article: The University of Arkansas for Medical Sciences and Drs. G.Z., M.H.-J., P.A.C., and C.M.C. have financial interests in (2R,8′S,3′E)-δ-tocodienol discussed in this report. These financial interests have been reviewed and approved in accordance with the university's conflict of interest policies. The authors would like to apologise for any inconvenience caused.

Idioma originalEnglish (US)
Páginas (desde-hasta)5943
Número de páginas1
PublicaciónTetrahedron
Volumen72
N.º39
DOI
EstadoPublished - 2016
Publicado de forma externa

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Organic Chemistry

Huella

Profundice en los temas de investigación de 'Erratum: Corrigendum to ‘Synthesis of (2R,8′S,3′E)-δ-tocodienol, a tocoflexol family member designed to have a superior pharmacokinetic profile compared to δ-tocotrienol’ (Tetrahedron (2016) 72(27–28) (4001–4006))'. En conjunto forman una huella única.

Citar esto